s-488211
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 30, 2019 (NCT04316689)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04106115 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2019 | AstraZeneca, Shionogi, University of London |
| NCT04316689 | Phase 1 | Jul 30, 2019 | Shionogi |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shionogi | For profit | 2 | 1 | 2 | 2019 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2019 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1